This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
Annals of Hematology Open Access 02 September 2023
-
DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation
BMC Cancer Open Access 27 August 2020
-
Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma
Blood Cancer Journal Open Access 09 October 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
Ngo V, Ryan M, Schmitz R, Jhavar S, Xiao W, Lim K et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.
Jiménez C, Sebastián M, Chillón M, Giraldo P, Mariano J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia 2013; 27: 1722–1728.
Krol ADG, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM . Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003; 14: 131–139.
Choi J-W, Kim Y, Lee J-H, Kim Y-S . MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 2013; 44: 1375–1381.
Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203–5211.
Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 2013; 3: e139.
Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2014; 53: 144–153.
Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJM, MECM Oud, Noorduyn LA et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2013; 28: 719–720.
Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP . MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2012; 132: 2118–2120.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.
Young RM, Staudt LM . Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229–243.
Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 2013; 122: 1222–1232.
Treon S, Tripsas C, Yang G, Cao Y, Xu L, Hunter Z et al. A prospective, multicentre, phase II study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenstrom’s macroglobulinemia. Hematol Oncol 2013; 31 (Suppl 1): 119 (abstract 067).
Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood (ASH Annu Meet Abstr) 2012; 120, abstract 686.
Acknowledgements
This work was supported by RD09/0076/0036, PT13/0010/0005, 2014 SGR 567 and the ‘Xarxa de Bancs de tumors’ sponsored by Pla Director d'Oncologia de Catalunya (XBTC). CF-R received a fellowship from the Ministry of Economy and Competitiveness of Spain (PFIS grant FI11/00353).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Fernández-Rodríguez, C., Bellosillo, B., García-García, M. et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia 28, 2104–2106 (2014). https://doi.org/10.1038/leu.2014.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.184
This article is cited by
-
Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
Annals of Hematology (2023)
-
DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation
BMC Cancer (2020)
-
Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib
Targeted Oncology (2020)
-
Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma
Blood Cancer Journal (2018)
-
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
Journal of Hematology & Oncology (2017)